Clinical trials using neural stem cells
Neural stem cells (mouse)
Allogeneic (single donor) neural stem cells are being investigated for their potential in treating spinal cord injuries. There are several clinical trials examining human neural stem cells in spinal cord injuries (see clinicaltrials.gov). These trials inject neural stem cells directly into the spinal cord with the hope that the cells help re-establish some of the connections between neurons and create the necessary cells to support both the old and new neurons.
In December 2010 the Swiss regulatory agency for therapeutic products approved a StemCell Inc. sponsored Phase I/II clinical trial on chronic spinal cord injury at the Balgrist University Hospital in Zurich (Switzerland). The trial used specific stem cells derived from human brain tissue (neural stem cell or NSCs), which can make any of the three major kinds of neural cells found in the central nervous system. The trial was based on preclinical evidence that oligodendrocyte cells were replaced after transplanting human NSCs into in a particular mouse model for spinal cord injuries. For the trial, human NSCs (specifically referred to as Human Central Nervous System Stem Cells or HuCNS-SC) were directly implanted into the spinal cord of patients with complete and incomplete chronic thoracic spinal cord injuries. This trial was officially completed in June 2015 (clinicaltrials.gov identifier no. NCT01321333). In 2012 a further Phase I/II clinical study of HuCNS-SC cell transplantation was started with 12 subjects (clinicaltrials.gov identifier no. NCT01725880) and in 2014 another clinical trial was started to test the safety and efficacy of HuCNS-SC transplantation in cervical spinal cord injuries (clinicaltrials.gov identifier no. NCT02163876). After having treated 12 patients in the NCT01321333 phase I/II trial and additional 31 in the NCT02163876 phase II trial (total 43 patients) the company reported no serious adverse effects. However, Stem Cell Inc. prematurely terminated its stem cell programmes in 2016 following an in-depth review of data from these studies. The outcomes appear to have been safe, but were not as effective as the company was aiming for. Stemcells Inc. is the second high-profile cellular therapy developer to fall short in the highly challenging neural therapies space in recent years.
In 2014 Neuralstem began a Phase I safety trial of its NSI-566 neural stem cells for chronic spinal cord injury at the University of California, San Diego School of Medicine (clinicaltrials.gov identifier no. NCT01772810). This trial uses the same cells and a similar procedure as the companys Amyotrophic Lateral Sclerosis (ALS) trials (the first FDA-approved neural stem cell trial for the treatment of ALS). The 2014 trial will include a total of 8 patients, four of whom have thoracic spinal cord injuries causing complete loss of sensory and motor function. This trial is currently recruiting with an estimated completion of treatments in 2018 and study results in 2022.
The Miami Project clinical researchers currently have several clinical trials and clinical studies available for people who have had a spinal cord injury; some are for acute injuries and some are for chronic injuries. The clinical trials are testing the safety and efficacy of different cellular, neuroprotective, reparative, or modulatory interventions. These include a Phase I clinical trial with patients own myelinating cells, cells derived from the peripheral nervous system Schwann cells (clinicaltrials.gov identifier no. NCT01739023). The Miami Project is also sponsoring a Phase I clinical trial of autologous human Schwann cell (ahSC) transplantation in participants with chronic spinal cord injuries (clinicaltrials.gov identifier no. NCT02354625). While the former trial was completed in 2017, the latter is currently recruiting - approximately until January 2019.
Mesenchymal/stromal stem cells are being investigated as possible treatments for spinal cord injuries. Clinical Trials (clinicaltrials.gov) identifies at present total of 16 trials tagged as MSC trials in spinal cord injuries. These include studies that investigate the safety and efficacy of MSCs derived from the patients own bone marrow (9), adipose tissue (fat) (5) or cord blood (2). MSCs are injected in a number of different ways in these trials - including directly into the spinal cord or the lesion itself, intravenously, or even just in the skin. The hope is that when transplanted into the injured spinal cord, these cells provide tissue protective molecules and help to re-establish some of the circuitries important for the network of nerves (indirectly from cell integration and differentiation). More information can be found here.
California based biotech Geron had a widely reported clinical trial under way for a treatment the first of its kind involving the injection of cells derived from human embryonic stem cells. The injected cells were precursors of oligodendrocytes, the cells that form the insulating myelin sheath around axons. Researchers hoped that these cells, once injected into the spinal cord, would mature and form a new coating on the nerve cells, restoring the ability of signals to cross the spinal cord injury site.
After treating four patients with these cells in a Phase I clinical trial and reporting no serious adverse effects, Geron announced in November 2011 it was discontinuing its stem cell programme. The company said stem cells continue to hold great promise, but cited financial reasons for shifting focus to other areas of research.
Following up on the cellular technology initially developed by Geron, Asterias Biotherapeutics has developed a program that focuses on treating spinal cord injuries with specially developed oligodendrocyte progenitor cells (OPCs), precursors of oligodendrocytes. These cells, known as AST-OPC1, are produced from human embryonic stem cells. The hope is that when transplanted into the injured spinal cord abruptly after injury (7-14 days), OPCs may re-myelinate and restore lost functions.
In a Phase I clinical trial, five patients with neurologically complete, thoracic spinal cord injury were administered embryonic stem cell-derived OPCs at the site of injury. Delivery of OPCs was successful in all five subjects and no serious adverse events were associated with either the administered cells or the accompanying immunosuppression regimen. In four of the five subjects, MRI scans suggested a reduction in the volume of spinal cord injury.
A second follow up (dose escalation) Phase I/II trial with AST-OPC1 in acute (14-30 days after injury) sensorimotor complete cervical spinal cord injuries is currently recruiting participants (clinicaltrials.gov identifier no. NCT02302157).
View original post here:
Spinal cord injuries: how could stem cells help ...
- Standardized production of hPSC-derived cardiomyocyte aggregates in stirred spinner flasks - Nature.com - March 28th, 2024
- Synthetic Circuits Reveal the Key to Rewinding the Cellular Clock - The Scientist - March 13th, 2024
- synNotch-programmed iPSC-derived NK cells usurp TIGIT and CD73 activities for glioblastoma therapy - Nature.com - March 3rd, 2024
- Breaking through new research barriers with iPSC technology - News-Medical.Net - February 15th, 2024
- Abu Dhabi Stem Cells Centre partners with Rege Nephro and Kyoto University's Center for iPS Cell Research and ... - Abu Dhabi Media Office - January 12th, 2024
- Abu Dhabi Stem Cells Center partners with Japan-based Kyoto University and Rege Nephro - ZAWYA - January 12th, 2024
- Efficient and reproducible generation of human induced pluripotent stem cell-derived expandable liver organoids for ... - Nature.com - December 23rd, 2023
- Mechanisms, pathways and strategies for rejuvenation through epigenetic reprogramming - Nature.com - December 15th, 2023
- Shinobi Therapeutics Launches with Completion of $51M Series A to Advance Hypoimmune iPS-T Cell Therapy Platform - PR Newswire - December 13th, 2023
- CRISPRi gene modulation and all-optical electrophysiology in post-differentiated human iPSC-cardiomyocytes ... - Nature.com - December 7th, 2023
- World Hindu Congress 2023: Know all about the sessions and speakers - Organiser - November 23rd, 2023
- VCCT Inc., Leading the Field of Retinal Regeneration through iPS ... - Business Wire - November 21st, 2023
- Efficient protocol for the differentiation of kidney podocytes from ... - Nature.com - November 17th, 2023
- Vitamin B12 is a limiting factor for induced cellular plasticity and ... - Nature.com - November 17th, 2023
- Study reveals the critical role of microglia in human brain development - Medical Xpress - November 15th, 2023
- VCCT Inc., Leading the Field of Retinal Regeneration through iPS Cells, Raises 600 million Japanese yen (approximately $4 million USD) through... - November 15th, 2023
- Who are the leading innovators in iPSCs for the pharmaceutical ... - Pharmaceutical Technology - November 7th, 2023
- Using iPS Cells from I Peace, Heartseed Succeeds in Stable Production of High Purity Cardiomyocytes, A Major Step Forward in Advancing Autologous... - November 5th, 2023
- Systematic differences in discovery of genetic effects on gene ... - Nature.com - October 21st, 2023
- Pairwise biosynthesis of ion channels stabilizes excitability and ... - pnas.org - October 11th, 2023
- Scientists find multitude of genes associated with autism - The Statesman - October 9th, 2023
- Stem Cell Banking Market is Expected to Reach USD 16,474.30 ... - Digital Journal - October 7th, 2023
- Probing the individuality of cells and molecules - Open Access Government - October 5th, 2023
- Thymmune Therapeutics Receives $37M in Funding from the ... - Manchestertimes - October 3rd, 2023
- Thymmune Therapeutics Receives $37M in Funding from the ... - Business Wire - September 29th, 2023
- Less Funding to More Researchers Gets Nobel-level Results, Study ... - The Japan News - September 27th, 2023
- Brentuximab Vedotin Plus AVD Gets Positive CHMP Opinion for ... - OncLive - September 20th, 2023
- DKMS BMST Foundation India and Kokilaben Hospital unite to spread awareness about the Importance of Stem Cell Donation on World Marrow Donor Day - APN... - September 18th, 2023
- Vitamin B6 is governed by the local compartmentalization of ... - Science - September 14th, 2023
- Dolly the sheep creator Ian Wilmut dies aged 79 - BBC - September 14th, 2023
- Scientist who created Dolly the sheep dies aged 79: Professor Sir Ian Wilmut passes away five years after reve - Daily Mail - September 11th, 2023
- The global kits market is expected to grow at a CAGR of 7.4% from ... - Digital Journal - September 8th, 2023
- Eterna Therapeutics Announces Initiation of Development Activities ... - PipelineReview.com - September 8th, 2023
- Tokyo: 100 Years of Urban Regeneration / Tokyo's Nihonbashi Area ... - The Japan News - August 31st, 2023
- Transcriptome-based prediction of drugs, inhibiting ... - Nature.com - August 30th, 2023
- From the birds and the bees to IVG - The Gauntlet - August 26th, 2023
- Breakthrough creates stem cells without any memories - Freethink - August 26th, 2023
- Aging impairs the neurovascular interface in the heart - Science - August 26th, 2023
- For This Venture Capitalist, Research on Aging Is Personal; 'Bob ... - The Wall Street Journal - August 22nd, 2023
- Unleashing Potential: Illuminating the Future of Healthcare through Revolutionary Induced Pluripotent Stem Cel - openPR - August 18th, 2023
- A 'memory wipe' for stem cells may be the key to better therapies - The Conversation - August 16th, 2023
- Erasing epigenetic 'memory' to improve the quality of stem cells - FierceBiotech - August 16th, 2023
- HebeCell and Logomix Announce Collaboration for the ... - Business Wire - August 16th, 2023
- HebeCell and Logomix Announce Collaboration for the ... - Valdosta Daily Times - August 11th, 2023
- Advancing Clinical Trials with iPSC-Derived Liver Organoids - Microbioz India - August 11th, 2023
- Activation of cAMP (EPAC2) signaling pathway promotes hepatocyte ... - Nature.com - August 1st, 2023
- IPS HEART Announces Peer-Reviewed Publication in Cells of Aging Damage Reversal Showing GIVI-MPC Stem Cell Therapys Ability to Create New Skeletal... - July 30th, 2023
- Femtech in Japan: An Industry on the Rise - Femtech Insider - July 28th, 2023
- Association between enhanced carbonyl stress and decreased ... - Nature.com - July 28th, 2023
- Defects in early synaptic formation and neuronal function in Prader ... - Nature.com - July 27th, 2023
- IPS HEART Announces Peer-Reviewed Publication in Cells of ... - Business Wire - July 25th, 2023
- Cure to Autism and Alzheimer's May Be in Space, Says 1st Brazilian Scientist who Will Be on The ISS - Folha de S.Paulo - July 25th, 2023
- Futurama's Resurrection Ruins The Perfect Ending (& Shows Must ... - Looper - July 25th, 2023
- University Of Massachusetts Amherst's Team Bags Honour Of 2023 Armstrong Fund For Science Award - India Education Diary - July 20th, 2023
- Scientists working on IVG, a new reproductive method that can make human babies in labs - IndiaTimes - July 19th, 2023
- Co-transplantation of autologous Treg cells in a cell therapy for ... - Nature.com - July 13th, 2023
- Magic Valley and Biocellion Join Forces to Improve Bioreactor Tech ... - vegconomist - the vegan business magazine - July 13th, 2023
- IPS HEART Receives U.S. FDA Rare Pediatric Drug Designation for ... - Tullahoma News and Guardian - July 10th, 2023
- Hitachi : forms strategic research collaboration with Mass General Brigham in the field of regenerative medicine and GCT - Marketscreener.com - July 6th, 2023
- Cell therapy limitations with iPS-based multi-cell therapeutics - Drug Target Review - July 6th, 2023
- Remembering Dolly- The Clone Sheep On Her Birth Anniversary - Free Press Journal - July 4th, 2023
- Labs and Translational Research - UMass Medical School - June 28th, 2023
- Cellusion raises 2.83B series C round to progress iPS cell-derived ... - BioWorld Online - June 14th, 2023
- Japan-based Fujifilm introduces first-of-its-kind human iPSC-derived ... - BSA bureau - June 6th, 2023
- ALS: Parkinson's drug ropinirole may be an effective treatment - Medical News Today - June 4th, 2023
- Scientists predict lab-grown babies in five years - Kidspot - June 4th, 2023
- Lab-grown babies could become a reality within five years - Earth.com - May 26th, 2023
- Leading healthcare experts from MENA and beyond to explore the future of precision medicine in the region at PMES 23 this month - ZAWYA - May 24th, 2023
- Long-Awaited Ax-2 Mission Launches, Heads to Space Station - AmericaSpace - May 22nd, 2023
- Eterna Therapeutics and Factor Bioscience Announce New Data on ... - GlobeNewswire - May 17th, 2023
- Research Assistant job with UNITED ARAB EMIRATES ... - Times Higher Education - May 10th, 2023
- Regulation of synaptic connectivity in schizophrenia spectrum by ... - Nature.com - April 29th, 2023
- Researchers Discover Key Role of Glucose in Brain Activity - Laboratory Equipment - April 25th, 2023
- Structure of Huntington's Protein Revealed - Technology Networks - April 21st, 2023
- Study of brain immune cell infection may explain long COVID ... - NHK WORLD - April 19th, 2023
- The Mechanism That Regulates Activity of Memory Gene - Neuroscience News - April 19th, 2023
- The IPO Buzz: CytoMed Therapeutics Prices its Micro-Cap IPO at ... - IPOScoop - April 19th, 2023
- Macomics Presents its ENIGMAC Discovery Platform for Gene to Function Target Validation of Novel Macrophage Therapies at AACR - Yahoo Finance - April 19th, 2023
- Modulation of tau tubulin kinases (TTBK1 and TTBK2) impacts ... - Nature.com - April 19th, 2023
- A Cdk5-derived peptide inhibits Cdk5/p25 activity and improves ... - pnas.org - April 16th, 2023
Recent Comments